{"id":"NCT01580670","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease","officialTitle":"Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2012-04-19","resultsPosted":"2019-07-05","lastUpdate":"2019-07-24"},"enrollment":14,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Crohn's Disease"],"interventions":[{"type":"DRUG","name":"TA-650","otherNames":["Infliximab"]}],"arms":[{"label":"TA-650","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy of TA-650 using Pediatric Crohn's Disease Activity Index (PCDAI) in pediatric patients with moderate to severe Crohn's disease after TA-650 administration at a dose of 5 mg/kg at week 0, 2, and 6, then every 8 week after week 14 up to week 46, and at a dose of 10 mg/kg if the effect is attenuated. The safety and pharmacokinetics are also evaluated.","primaryOutcome":{"measure":"Percent of Patients Who Achieved PCDAI Response","timeFrame":"Week 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, and the last time point during the period from administration of the study drug to Week 54","effectByArm":[{"arm":"TA-650","deltaMin":78.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["30114224"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":14},"commonTop":["Double stranded DNA antibody positive","Gastroenteritis","Nasopharyngitis","Headache","Influenza"]}}